JP2018533560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533560A5 JP2018533560A5 JP2018517826A JP2018517826A JP2018533560A5 JP 2018533560 A5 JP2018533560 A5 JP 2018533560A5 JP 2018517826 A JP2018517826 A JP 2018517826A JP 2018517826 A JP2018517826 A JP 2018517826A JP 2018533560 A5 JP2018533560 A5 JP 2018533560A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- compound
- cancer
- administering
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- -1 adamantane compound Chemical class 0.000 claims 11
- 230000003115 biocidal Effects 0.000 claims 11
- 229940079593 drugs Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 5
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 5
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 5
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 5
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 5
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 229940079866 intestinal antibiotics Drugs 0.000 claims 5
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- GKNUOVITASQZAQ-AWEZNQCLSA-N ethyl 4-[(2S)-2-amino-3-phenylpropanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](N)CC1=CC=CC=C1 GKNUOVITASQZAQ-AWEZNQCLSA-N 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- OECLPECEPAYMGH-UHFFFAOYSA-N 3-(4-chlorophenyl)adamantane-1-carboxylic acid Chemical compound C1C(C(=O)O)(C2)CC(C3)CC1CC32C1=CC=C(Cl)C=C1 OECLPECEPAYMGH-UHFFFAOYSA-N 0.000 claims 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N Clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims 3
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 3
- 229960002626 clarithromycin Drugs 0.000 claims 3
- 230000002519 immonomodulatory Effects 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 3
- 101700070750 inh Proteins 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 3
- 229960000885 rifabutin Drugs 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 230000036091 Metabolic activity Effects 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000001516 cell proliferation assay Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 230000002503 metabolic Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 229960004117 Capecitabine Drugs 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- FGYMBVGBIYRUHB-UQKRIMTDSA-N S(=O)(=O)(O)O.C(C)OC(=O)N1CCN(CC1)C([C@@H](N)CC1=CC=CC=C1)=O Chemical compound S(=O)(=O)(O)O.C(C)OC(=O)N1CCN(CC1)C([C@@H](N)CC1=CC=CC=C1)=O FGYMBVGBIYRUHB-UQKRIMTDSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237925P | 2015-10-06 | 2015-10-06 | |
| US62/237,925 | 2015-10-06 | ||
| PCT/IB2016/001526 WO2017060771A2 (en) | 2015-10-06 | 2016-10-06 | Combination therapies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533560A JP2018533560A (ja) | 2018-11-15 |
| JP2018533560A5 true JP2018533560A5 (US07981874-20110719-C00313.png) | 2019-11-14 |
| JP6963545B2 JP6963545B2 (ja) | 2021-11-10 |
Family
ID=58446480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517826A Active JP6963545B2 (ja) | 2015-10-06 | 2016-10-06 | 癌を治療するための併用療法 |
Country Status (12)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170070234A (ko) | 2014-10-24 | 2017-06-21 | 레드힐 바이오파마 엘티디 | 단일 가닥 ｒｎａ 바이러스 복제의 억제를 위한 요법 |
| EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| CA3063450A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| JP7397672B2 (ja) | 2017-06-26 | 2023-12-13 | ルネラ・バイオテック・インコーポレーテッド | ミトケトシン：癌細胞におけるケトン代謝を標的とするミトコンドリアに基づく治療薬 |
| EP3681494A4 (en) * | 2017-09-15 | 2021-08-04 | Ampersand Biopharmaceuticals, Inc. | INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES |
| MX2021008591A (es) * | 2019-01-16 | 2021-10-13 | Apogee Biotechnology Corp | Métodos para inducir una respuesta inmunitaria contra el cancer. |
| WO2020154716A1 (en) * | 2019-01-26 | 2020-07-30 | University Of Rochester | Compositions and methods for treating prostate cancer |
| US11045453B1 (en) | 2020-03-10 | 2021-06-29 | Redhill Biopharma Ltd. | Serine protease inhibitor for treating coronavirus infection |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795871A (en) | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| JP4603162B2 (ja) * | 1998-07-20 | 2010-12-22 | ヴィレックス アクチェンゲゼルシャフト | 新規ウロキナーゼインヒビター |
| AUPR644301A0 (en) * | 2001-07-17 | 2001-08-09 | Unisearch Limited | Method and composition for treatment of cancer |
| US6864264B1 (en) * | 2002-08-20 | 2005-03-08 | Gloria L. Anderson | 1-adamantyl chalcones for the treatment of proliferative disorders |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US20060142304A1 (en) * | 2004-12-27 | 2006-06-29 | Michael Southall | Method for treating or preventing pruritic and neurogenic skin disorders |
| US20060270631A1 (en) * | 2005-05-26 | 2006-11-30 | Smith Charles D | Methods for the treatment and prevention of angiogenic diseases |
| BRPI0611966B1 (pt) * | 2005-06-17 | 2022-05-03 | Apogee Biotechnology Corporation | Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| US20080226624A1 (en) * | 2007-03-07 | 2008-09-18 | Wolfgang Schmalix | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect |
| ES2708087T3 (es) * | 2008-02-08 | 2019-04-08 | Red Hill Biopharma Ltd | Procedimientos y composiciones para tratar enfermedad inflamatoria intestinal |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| MX370688B (es) * | 2012-08-30 | 2019-12-19 | Texas A & M Univ Sys | Composiciones y métodos para sensibilización con fármaco o inhibición de una célula de cáncer. |
| KR20170070234A (ko) * | 2014-10-24 | 2017-06-21 | 레드힐 바이오파마 엘티디 | 단일 가닥 ｒｎａ 바이러스 복제의 억제를 위한 요법 |
-
2016
- 2016-10-06 AU AU2016336133A patent/AU2016336133B2/en not_active Ceased
- 2016-10-06 JP JP2018517826A patent/JP6963545B2/ja active Active
- 2016-10-06 US US15/287,381 patent/US9844540B2/en active Active
- 2016-10-06 BR BR112018003232A patent/BR112018003232A2/pt not_active IP Right Cessation
- 2016-10-06 EP EP16853154.9A patent/EP3359255A4/en active Pending
- 2016-10-06 KR KR1020187007757A patent/KR20180058716A/ko not_active Application Discontinuation
- 2016-10-06 MX MX2018004309A patent/MX2018004309A/es unknown
- 2016-10-06 WO PCT/IB2016/001526 patent/WO2017060771A2/en active Application Filing
- 2016-10-06 CA CA2997671A patent/CA2997671A1/en not_active Abandoned
- 2016-10-06 RU RU2018109902A patent/RU2727474C2/ru active
- 2016-10-06 CN CN201680058309.3A patent/CN108136207A/zh active Pending
-
2017
- 2017-11-07 US US15/805,682 patent/US10463654B2/en active Active
-
2019
- 2019-01-31 HK HK19101708.0A patent/HK1259342A1/zh unknown
- 2019-09-17 US US16/573,325 patent/US10946000B2/en active Active
-
2021
- 2021-01-12 US US17/147,093 patent/US11633385B2/en active Active
